drugset / Trial / NCT04840823

Enoxacin for Amyotrophic Lateral Sclerosis (ALS)

NCT04840823

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will assess the safety of the drug enoxacin at specific dose levels in adults with ALS.

Timeline

Start
2021-03-26
Primary completion
2023-11-15
Completion
2023-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Enoxacin Small molecule 200 mg Oral
Subject Enoxacin Small molecule 400 mg Oral
Subject Enoxacin Small molecule 600 mg Oral